Oxcarbazepine Therapy in Very Young Children: A Single-Center Clinical Experience

Oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and children ≥4 years of age. The purpose of this retrospective chart review was to assess efficacy and tolerability of oxcarbazepine in children ≤4 years of age. A single-center re...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric neurology 2006-09, Vol.35 (3), p.173-176
Main Authors: Kothare, Sanjeev V., Mostofi, Navid, Khurana, Divya S., Mohsem, Bashar, Melvin, Joseph J., Hardison, Huntley H., Valencia, Ignacio, Legido, Agustin
Format: Article
Language:English
Subjects:
Age Factors
Anticonvulsants - administration & dosage
Anticonvulsants - therapeutic use
Bacterial diseases
Biological and medical sciences
Carbamazepine - administration & dosage
Carbamazepine - analogs & derivatives
Carbamazepine - therapeutic use
Child, Preschool
Epilepsy - drug therapy
Female
Follow-Up Studies
Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy
Human bacterial diseases
Humans
Infant
Infectious diseases
Male
Medical sciences
Nervous system (semeiology, syndromes)
Neurology
Retrospective Studies
Treatment Outcome
Tuberculosis and atypical mycobacterial infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and children ≥4 years of age. The purpose of this retrospective chart review was to assess efficacy and tolerability of oxcarbazepine in children ≤4 years of age. A single-center retrospective chart review of patients ≤4 years old with epilepsy receiving oxcarbazepine between 2001 to 2004 was conducted. Twenty patients (male = 13, female = 7; ages 6-45 months [mean age 22.8 months]) who received oxcarbazepine were identified. Seizure types included partial onset (75%), symptomatic generalized (15%), and other (n = 2, 10%). Oxcarbazepine doses ranged between 14-71 mg/kg/day (mean dose: 36.5 mg/kg/day). Oxcarbazepine was prescribed as monotherapy in 15 patients and as first-line therapy in 73% patients. Overall, 70% experienced a significant reduction in seizures, and 50% became seizure-free while receiving oxcarbazepine. Transient drowsiness was reported in 20% of patients during dose escalation. No adverse events were observed in children
ISSN:0887-8994
1873-5150
DOI:10.1016/j.pediatrneurol.2006.03.003